Surf early to higher tides : surfactant therapy to optimize tidal volume, lung recruitment, and iNO response
Inhaled nitric oxide is approved by FDA for the management of hypoxemic respiratory failure in term and near-term infants. However, approximately a third of patients treated with inhaled nitric oxide fail to have a sustained improvement in oxygenation. Recruitment of the lung with surfactant enables optimal delivery of nitric oxide to the alveolar space leading to effective pulmonary vasodilation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Journal of perinatology : official journal of the California Perinatal Association - 41(2021), 1 vom: 13. Jan., Seite 1-3 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Konduri, Girija G [VerfasserIn] |
---|
Links: |
---|
Themen: |
31C4KY9ESH |
---|
Anmerkungen: |
Date Completed 31.08.2021 Date Revised 02.01.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41372-020-0764-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM313673063 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM313673063 | ||
003 | DE-627 | ||
005 | 20231225151058.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41372-020-0764-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1045.xml |
035 | |a (DE-627)NLM313673063 | ||
035 | |a (NLM)32792634 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Konduri, Girija G |e verfasserin |4 aut | |
245 | 1 | 0 | |a Surf early to higher tides |b surfactant therapy to optimize tidal volume, lung recruitment, and iNO response |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.08.2021 | ||
500 | |a Date Revised 02.01.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Inhaled nitric oxide is approved by FDA for the management of hypoxemic respiratory failure in term and near-term infants. However, approximately a third of patients treated with inhaled nitric oxide fail to have a sustained improvement in oxygenation. Recruitment of the lung with surfactant enables optimal delivery of nitric oxide to the alveolar space leading to effective pulmonary vasodilation | ||
650 | 4 | |a Editorial | |
650 | 7 | |a Pulmonary Surfactants |2 NLM | |
650 | 7 | |a Surface-Active Agents |2 NLM | |
650 | 7 | |a Nitric Oxide |2 NLM | |
650 | 7 | |a 31C4KY9ESH |2 NLM | |
700 | 1 | |a Lakshminrusimha, Satyan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of perinatology : official journal of the California Perinatal Association |d 1993 |g 41(2021), 1 vom: 13. Jan., Seite 1-3 |w (DE-627)NLM01262943X |x 1476-5543 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2021 |g number:1 |g day:13 |g month:01 |g pages:1-3 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41372-020-0764-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2021 |e 1 |b 13 |c 01 |h 1-3 |